What Clinicians Should Expect Next May 11, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 1,409 views The rapid rise of GLP-1 receptor agonists has transformed diabetes treatment and obesity management over the past decade
10.1016/S0899-9007(02)00930-9 51
Quick Answer: Mounjaro (tirzepatide) can generally be taken safely alongside beta blockers, with no absolute contraindication to their combined use in patients with type 2 diabetes and cardiovascular conditions
Furthermore, if Orforglipron is successfully commercialized, Chugai will also be entitled to royalties for patent usage
I don't know if you can see it but behind me Dr